0000000000149698

AUTHOR

L.a. De Parseval

showing 2 related works from this author

Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma

2017

0301 basic medicinebusiness.industryMelanomaMutantBinimetinibHematologymedicine.disease03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisEncorafenibmedicineCancer researchbusiness
researchProduct

Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-muta…

2017

Oncologymedicine.medical_specialtybusiness.industryMelanomaMutantBinimetinibHematologymedicine.disease030226 pharmacology & pharmacyDermatology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOncologychemistryInternal medicineEncorafenibmedicinebusinessVemurafenib030217 neurology & neurosurgerymedicine.drugAnnals of Oncology
researchProduct